PMS-MOCLOBEMIDE 300 MG
MOCLOBEMIDE : 300 MG · DIN 02243219 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-MOCLOBEMIDE?
PMS-MOCLOBEMIDE 300 MG contains MOCLOBEMIDE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02243219, held by PHARMASCIENCE INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 04-Jul-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02243219 |
|---|---|
| Brand name | PMS-MOCLOBEMIDE |
| Generic / active ingredient | MOCLOBEMIDE : 300 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AG02 MOCLOBEMIDE |
| AHFS class | 28:16.04.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 04-Jul-2025 |
| Original market date | 2001-01-08 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code N06AG02 MOCLOBEMIDE. 4 of 21 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MANERIX | 300 MG | TABLET | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02166747 |
| MOCLOBEMIDE | 100 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02232148 |
| MOCLOBEMIDE | 150 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02232150 |
| MOCLOBEMIDE | 300 MG | TABLET | AA PHARMA INC | MARKETED | DIN 02240456 |
| DOM-MOCLOBEMIDE TABLETS 150MG | 150 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243348 |
| DOM-MOCLOBEMIDE TABLETS 300MG | 300 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02243349 |
| MANERIX | 150 MG | TABLET | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00899356 |
| MANERIX TAB 100MG | 100 MG | TABLET | HOFFMANN-LA ROCHE LIMITED | CANCELLED POST MARKET | DIN 00899348 |
| MOCLOBEMIDE-100 | 100 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02236928 |
| MOCLOBEMIDE-150 | 150 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02236929 |
Who else supplies MOCLOBEMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MOCLOBEMIDE appears in 119 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.